Page last updated: 2024-10-20

uracil and Anticipatory Vomiting

uracil has been researched along with Anticipatory Vomiting in 7 studies

2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder

Research Excerpts

ExcerptRelevanceReference
"We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer."9.12[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006)
"We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer."5.12[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006)
"Concomitant treatment with 5-fluorouracil (5-FU) and Leucovorin (LV) is positioned as the standard chemotherapy against colorectal cancer."3.72[Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer]. ( Anazawa, S; Hirai, K; Kawahara, H; Ogawa, M; Sakuyama, T; Sato, K; Takao, Y; Yamazaki, Y; Yokoyama, M, 2004)
"Uracil-tegafur (UFT) has been reported to have broad antitumor activity in a variety of malignancies."2.71A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Okusaka, T; Ueno, H, 2005)
"Tegafur is a prodrug that is converted to 5-fluorouracil (5-FU) and has been reported to be less toxic and to have a higher therapeutic index."1.31Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience. ( Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Hsu, TC; Jiang, JK; Lin, JK; Lin, TC; Liu, JH; Wang, HS; Wang, WS; Yang, SH; Yen, CC, 2000)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sakuyama, T1
Yokoyama, M1
Ogawa, M1
Takao, Y1
Sato, K1
Kawahara, H1
Anazawa, S1
Yamazaki, Y1
Hirai, K1
Ikeda, M1
Okusaka, T1
Ueno, H1
Morizane, C1
Furuse, J1
Ishii, H1
Ito, T1
Hata, Y1
Matsuoka, S1
Nakajima, N1
Yokoyama, R1
Honda, S1
Sano, F1
Akasaka, Y1
Ohmori, K1
Ishida, H1
Akita, H1
Watanabe, Y1
Nakaguchi, K1
Kabuto, T1
Sato, Y1
Inaba, Y1
Yamaura, H1
Shimamoto, H1
Nishiofuku, H1
Oyama, T1
Kanemitsu, Y1
Sawaki, A1
Arai, Y1
Muro, K1
Inaji, H1
Sakai, K1
Oka, T1
Ozawa, K1
Saito, Y1
Senoo, T1
Taguchi, T1
Terasawa, T1
Nakao, K1
Mori, T1
Koyama, H1
Oshima, A1
Lin, JK1
Wang, WS1
Hsieh, RK1
Hsu, TC1
Chiou, TJ1
Liu, JH1
Fan, FS1
Yen, CC1
Lin, TC1
Jiang, JK1
Yang, SH1
Wang, HS1
Chen, PM1

Trials

3 trials available for uracil and Anticipatory Vomiting

ArticleYear
A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Drug Adm

2005
[Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug A

2005
[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:10

    Topics: Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Ne

2006

Other Studies

4 other studies available for uracil and Anticipatory Vomiting

ArticleYear
[Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administration

2004
[Complete response to CPT-11 and UFT/LV combination therapy in a case with simultaneous multiple lung metastases from colon cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6

    Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neop

2006
[Retrospective analysis of tegafur/uracil (UFT) plus oral leucovorin (LV) regimen in patients with advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2006
Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience.
    Japanese journal of clinical oncology, 2000, Volume: 30, Issue:11

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2000